October 11, 2007 - Omnicell Inc., a provider of system solutions to acute healthcare for improving patient safety and efficiency, said today introduced its WorkflowRx 5.0 central pharmacy automation solution.
With a new user-friendly graphical interface, the company says the Omnicell WorkflowRx 5.0 allows pharmacy staff to complete automated dispensing, unit-dose packaging and other inventory maintenance tasks simultaneously. The WorkflowRx 5.0 also increases productivity and efficiency through a unique intelligent hardware recovery management feature that frees staff to focus on direct patient care activities.
“The WorkflowRx solution provides us with the ability to manage every pharmaceutical in the hospital, whether it is stored in the central pharmacy, stocked in an automated cabinet, stored in a remote nursing destination, or in a satellite pharmacy location,” said David Grant, RPh, MBA, director of pharmacy and respiratory care, Chambersburg Hospital. “The WorkflowRx 5.0 solution is easy to use and maximizes the efficiency of pharmacists and technicians. After implementing the WorkflowRx solution, we’ve reduced our cart-fill time from 16 man-hours to 90 minutes. The result is a significantly streamlined pharmacy process with greater efficiency and patient safety and has enhanced our compliance with JHACO requirements.”
Omnicell WorkflowRx central pharmacy solutions automate the ordering, receiving, stocking, dispensing and unit-dose packaging of medications. It provides central pharmacy operations with greater patient safety and more efficient staff utilization, while decreasing medication inventory costs. The WorkflowRx 5.0 solution interfaces to Omnicell’s barcode packaging system and inventory management carousel system to manage 100 percent of the central pharmacy inventory and dispensing tasks.
Additional new features of the WorkflowRx 5.0 solution include an integrated 340B order process that tracks 340B-eligible drug usage and automatically generates 340B-specific purchase orders, allowing participating facilities to realize the benefits of 340B pricing without complicated management of drug utilization data.
For more information: www.omnicell.com